<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02108808</url>
  </required_header>
  <id_info>
    <org_study_id>PATRAS CARDIOLOGY 18</org_study_id>
    <nct_id>NCT02108808</nct_id>
  </id_info>
  <brief_title>Effect of Ticagrelor on Fractional Flow Reserve</brief_title>
  <official_title>Differential Effect of Ticagrelor vs Prasugrel or Clopidogrel Loading on Fractional Flow Reserve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fractional flow reserve (FFR) is an established invasive method for assessing the&#xD;
      physiological significance of coronary artery stenosis. Adenosine, an important endogenous&#xD;
      regulator of coronary blood flow during both stress and ischemia, is widely used to achieve&#xD;
      conditions of stable hyperemia required for measurement of FFR.&#xD;
&#xD;
      Studies in healthy volunteers and in patients with acute coronary syndrome (ACS) post&#xD;
      percutaneous coronary intervention (PCI) receiving ticagrelor revealed a differential&#xD;
      coronary blood flow velocity response during increasing doses of adenosine compared to&#xD;
      placebo or prasugrel treated subjects, respectively. It has also been demonstrated that&#xD;
      patients treated with ticagrelor have increased plasma adenosine levels. Therefore, it has&#xD;
      been hypothesized that the degree of hyperemia obtained with adenosine infusion may be&#xD;
      greater in patients on ticagrelor than that obtained in patients taking clopidogrel or&#xD;
      prasugrel. If this proves to be true, it would lead to a lower FFR value with possible&#xD;
      important clinical implications in ticagrelor receiving patients in need for FFR measurement.&#xD;
&#xD;
      This is a prospective, single center, randomized study of parallel design. Consecutive&#xD;
      ticagrelor naive patients who are referred for coronary angiography and have an&#xD;
      angiographically moderate to severe de novo stenosis (&gt;50% and &lt;90% diameter by visual&#xD;
      assessment) in at least one major epicardial coronary artery amenable to PCI are candidates&#xD;
      for this study. Patients after informed consent will be randomized (hour 0) to receive&#xD;
      immediately post FFR (with adenosine iintravenous infusion at 140 Î¼g/Kg/min for a 3 minute&#xD;
      period) either ticagrelor 180mg loading dose or prasugrel 60mg/clopidogrel 600mg loading dose&#xD;
      (as clinically indicated). FFR examination will be repeated 2 hours post loading dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% relative change in steady hyperemia FFR (sFFR)</measure>
    <time_frame>2 hours</time_frame>
    <description>Steady hyperemia FFR (sFFR) is defined as the FFR value attained during stable hyperemia (as assessed by offline visual inspection of the 3-min hemodynamic trace) (sFFR post drug - sFFR pre drug)*100/sFFR pre drug between the 2 treatment arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% relative change in peak hyperemia FFR (pFFR)</measure>
    <time_frame>2 hours</time_frame>
    <description>Peak hyperemia FFR is defined as the lowest FFR measurement during the first 60 sec of adenosine infusion (pFFR post drug - pFFR pre drug)*100/pFFR pre drug between the 2 treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% relative change in lowest FFR (lFFR)</measure>
    <time_frame>2 hours</time_frame>
    <description>Lowest FFR (lFFR) is defined as the value provided by the automated FFR console (lFFR post drug - lFFR pre drug)*100/lFFR pre drug between the 2 treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% relative change in time to peak FFR (in seconds)</measure>
    <time_frame>2 hours</time_frame>
    <description>(time to pFFR post drug - time to pFFR pre drug)*100/time to pFFR pre drug between the 2 treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% relative change in time to lowest FFR</measure>
    <time_frame>2 hours</time_frame>
    <description>(time to lFFR post drug - time to lFFR pre drug)*100/time to lFFR pre drug between the 2 treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% relative change in area under the curve (AUC) of the FFR trace</measure>
    <time_frame>2 hours</time_frame>
    <description>(AUC FFR post drug - AUC FFR pre drug)*100/AUC FFR pre drug between the 2 treatment arms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reclassification of coronary revascularization strategy at hour 2 in relation to hour 0</measure>
    <time_frame>2 hours</time_frame>
    <description>Number of patients who were reclassified regarding revascularization strategy at hour 2 in relation to hour 0, between the 2 treatment arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Fractional Flow Reserve</condition>
  <arm_group>
    <arm_group_label>Prasugrel or Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prasugrel 60mg or Clopidogrel 600mg loading dose, as clinically indicated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 180mg loading dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel or Clopidogrel</intervention_name>
    <arm_group_label>Prasugrel or Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-80 years&#xD;
&#xD;
          2. Patients subjected to clinically indicated coronary angiography with at least one&#xD;
             50%-90% stenosis at 1 major epicardial vessel (by visual assessment) amenable to&#xD;
             percutaneous coronary intervention.&#xD;
&#xD;
          3. Ticagrelor naive patients&#xD;
&#xD;
          4. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of coronary artery bypass surgery&#xD;
&#xD;
          2. Acute myocardial infarction within the previous 5 days&#xD;
&#xD;
          3. Known allergy to adenosine, ticagrelor, prasugrel or clopidogrel&#xD;
&#xD;
          4. Prior intracranial hemorrhage&#xD;
&#xD;
          5. Hemodialysis or creatinine clearance &lt; 30ml/h&#xD;
&#xD;
          6. Moderate/severe hepatic failure&#xD;
&#xD;
          7. Active bleeding, or at increased risk of bleeding&#xD;
&#xD;
          8. Left ventricular ejection fraction &lt;40%&#xD;
&#xD;
          9. Primary myocardial or valvular disease&#xD;
&#xD;
         10. Contraindication to adenosine&#xD;
&#xD;
         11. Angiographically visible thrombus at a target lesion, extremely tortuous coronary&#xD;
             arteries, severely calcified lesions, left main disease, anatomy suitable for coronary&#xD;
             artery bypass surgery&#xD;
&#xD;
         12. Previous q wave myocardial infarction in the area of target vessel&#xD;
&#xD;
         13. Severe left ventricular hypertrophy&#xD;
&#xD;
         14. Severe valvular heart disease&#xD;
&#xD;
         15. Heart failure as defined by New York Heart Association class III or IV 16.Hypotension&#xD;
             (blood pressure &lt;90 mm Hg)&#xD;
&#xD;
        17.Significant arrhythmia (e.g. excessive premature ventricular contractions or atrial&#xD;
        fibrillation), tachycardia (heart rate &gt;120 beats/min), bradycardia (&lt;50 beats/min),&#xD;
        increased risk for bradycardia 18.Caffeine consumption or cigarette smoking within the&#xD;
        previous 24 hours.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Patras University Hospital</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <last_update_submitted>January 4, 2015</last_update_submitted>
  <last_update_submitted_qc>January 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>Dimitrios Alexopoulos</investigator_full_name>
    <investigator_title>Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>FFR</keyword>
  <keyword>adenosine</keyword>
  <keyword>Ticagrelor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

